{"nctId":"NCT01180296","briefTitle":"Oral Progesterone for Prevention of Preterm Birth","startDateStruct":{"date":"2006-11"},"conditions":["Preterm Birth"],"count":36,"armGroups":[{"label":"Progesterone Group","type":"EXPERIMENTAL","interventionNames":["Drug: oral micronized progesterone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Identical Placebo tablet"]}],"interventions":[{"name":"oral micronized progesterone","otherNames":["Prometrium(TM)"]},{"name":"Identical Placebo tablet","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 \\& 0/7 weeks' and 36 \\& 6/7 weeks' gestation.\n\nExclusion Criteria:\n\n* multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Recurrent Preterm Birth","description":"Spontaneous preterm birth prior to 37 weeks' gestation. Indicated preterm deliveries (for maternal or fetal reasons) were excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Outcomes","description":"Serum progesterone levels","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.6","spread":"61.8"},{"groupId":"OG001","value":"90.1","spread":"38.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}}